AbbVie Inc.

$106.92 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About AbbVie Inc.

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Stock Analysis

last close $106.1
1-mo return -
3-mo return -1.1%
avg daily vol. 8M
52-week high 113.41
52-week low 78.66
market cap. $191.5B
forward pe 8.5
annual div. 5.2
roe 185.8%
ltg forecast 4.1%
dividend yield 4.9%
annual rev. $45.8B
inst own. 69.8%
baraka

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist